Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This will be a 12-week, multicenter, randomized, double-blind trial evaluating the efficacy,
safety, and tolerability of fixed-dose brexpiprazole + sertraline combination treatment in
adult subjects with post-traumatic stress disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.